Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fifty patients with metastatic renal cell carcinoma were treated with recombinant interleukin-2 alone or in combination with the antitumor drug vinblastine or lymphokine-activated killer cells. Of 34 evaluable patients treated with intravenous bolus interleukin-2, 1 (3%) had a partial response. Vinblastine increased myelotoxicity but did not enhance response to interleukin-2 in 15 of these patients. Two partial responses were observed among 15 patients treated with lymphokine-activated killer cells in addition to interleukin-2. In 1 patient biopsy documented complete resolution of hepatic metastases lasting for 1 year was observed. All responders had undergone previous nephrectomy and none had multiple sites of metastatic disease. Toxicity was significant and caused termination of therapy in 40% of the patients. Biological therapy using interleukin-2 can result in prolonged responses in renal cell cancer but future trials should be directed at lessening toxicity.
 ...
PMID:Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells. 834 90

A sensitive and specific high-performance liquid chromatographic method with fluorescence detection (excitation wavelength: 280 nm; emission wavelength: 360 nm) was developed and validated for the determination of vinorelbine in plasma and blood samples. The sample pretreatment procedure involved two liquid-liquid extraction steps. Vinblastine served as the internal standard. The system uses a Spherisorb cyano analytical column (250x4.6 mm I.D.) packed with 5 microm diameter particles as the stationary phase and a mobile phase of acetonitrile-80 mM ammonium acetate (50:50, v/v) adjusted to pH 2.5 with hydrochloric acid. The assay showed linearity from 1 to 100 ng/ml in plasma and from 2.5 to 100 ng/ml in blood. The limits of quantitation were 1 ng/ml and 2.5 ng/ml, respectively. Precision expressed as RSD was in the range 3.9 to 20% (limit of quantitation). Accuracy ranged from 92 to 120%. Extraction recoveries from plasma and blood averaged 101 and 75%, respectively. This method was used to follow the time course of the concentration of vinorelbine in human plasma and blood samples after a 10-min infusion period of 20 mg/m2 of this drug in patients with metastatic cancer.
 ...
PMID:High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study. 1108 81

A 69-year-old man who had developed multiple distant metastases on retrocaval lymph nodes after four courses of Methotraxate, Vinblastine, Adriamycin, Cisplatin (MVAC) chemotherapy was successfully treated by intravenous infusion of low-dose cisplatin (CDDP) (10 mg/time, once per week) and oral administration of 600 mg/day 5'-deoxy-5-fluorouridine (5'-DFUR), a pro-drug of 5-FU, in an outpatient setting. A partial response (62% reduction rate) was confirmed by abdominal computed tomography (CT) scan after 7 months. Although the CDDP dosage had been reduced to 5 mg/week 1 year previously, the tumor was still reducing in size in November 2000. Combination therapy of 5'-DFUR with low-dose CDDP could become an option for advanced bladder cancer that compromises the patient's quality of life, especially when used in an outpatient setting.
 ...
PMID:Metastatic urothelial cancer showing an efficacy by low-dose cisplatin. 1206 Apr 42

Surgical excision remains the only method of curing renal cell carcinoma. Early ligation of the renal artery and vein, followed by radical nephrectomy with regional lymphadenectomy, seems to offer the best method of cure for patients with localized disease. Results of more extensive surgery have been encouraging, and surgical extirpation should be attempted even when the tumor involves the vena cava, adjacent organs, or a solitary kidney. Radiotherapy as a post-operative adjuvant has not been effective, and when used pre-operatively, may decrease local recurrence but does not appear to improve five-year survival. A chemotherapeutic agent capable of significantly altering the course of metastastic renal cell carcinoma has not been identified. Vinblastine, the most effective currently available drug, rarely produces tumor regression. Progestational agents seldom, if ever, cause tumor regression, though newer hormonal agents may be more promising. Data continue to accumulate documenting altered immune mechanisms in renal cancer patients. These studies have provided impetus for continued trials of immunotherapy, and several agents are being studied. The management of patients with metastases at the time of diagnosis remains controversial. A better understanding of the natural history of these patients suggests that palliative nephrectomy may be inappropriate except for severe symptoms and patients with resectable metastases. Intraarterial infarction, fellowed by palliative nephrectomy, may improve survival, perhaps by stimulating a general immune response.
 ...
PMID:The Diagnosis and Treatment of Renal Cell Carcinoma. 2960 62


<< Previous 1 2 3